AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|
22.5 C
New York
Wednesday, September 9, 2026

Tag: plasma

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

TOMI Environmental Solutions Demonstrates SteraMist Efficacy in Combatting Honeybee Colony Collapse

FREDERICK, Md., June 23, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced significant advancements in the fight against the devastating honeybee colony collapse.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a...

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a...

Faraday Factory Japan signed an agreement to deliver superconductor tape for the demo stellarator magnet of Proxima Fusion

Proxima Fusion's first-of-a-kind power plant Stellaris will use high temperature superconductor magnets to confine the burning plasma TOKYO, June 20, 2025 /PRNewswire/ -- Proxima Fusion and Faraday Factory...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPlasma